(Q41025718)

English

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin

scientific article published on August 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin (English)

1 reference

Europe PubMed Central

25 September 2017

author name string

P K Schultz

1

1 reference

Europe PubMed Central

25 September 2017

W K Kelly

2

1 reference

Europe PubMed Central

25 September 2017

C Begg

3

1 reference

Europe PubMed Central

25 September 2017

C Liebertz

4

1 reference

Europe PubMed Central

25 September 2017

L Cohen

5

1 reference

Europe PubMed Central

25 September 2017

H I Scher

6

1 reference

Europe PubMed Central

25 September 2017

language of work or name

0 references

publication date

1 August 1994

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

44

1 reference

Europe PubMed Central

25 September 2017

237-242

1 reference

Europe PubMed Central

25 September 2017

2

1 reference

Europe PubMed Central

25 September 2017

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of adriamycin and its derivatives in the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate Specific Antigen Levels after Definitive Irradiation for Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate Specific Antigen and Prostatic Acid Phosphatase for Monitoring Therapy of Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate Specific Antigen for Assessing Response to Ketoconazole and Prednisone in Patients with Hormone Refractory Metastatic Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Suramin on Human Prostate Cancer Cells in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(94)80138-X

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41025718&oldid=2093326034"